• Planned use of GP IIb/IIIa inhibitors is safe and effective during implantation of the Absorb Bioresorbable Vascular Scaffold


    • First trial to evaluate the use of upfront GP IIb/IIIa inhibitors (GPI) to prevent acute scaffold thrombosis (ScT) during Bioresorbable Vascular Scaffold (BVS) implantation which demonstrates safety.
    • This 22-patient retrospective chart review demonstrated no ScT, in-hospital MACE, or in-hospital major/minor bleeding events during 27 BVS implantations.


    Bioresorbable Vascular Scaffolds (BVS) have the potential for adaptive vessel remodeling, restoration of vasomotion, and late luminal enlargement, thus allowing them to circumvent target lesion failures associated with bare metal stents (BMS) and drug-eluting stents (DES). However, recent data has shown a concerning increase in BVS-associated scaffold thrombosis(ScT) compared to DES. Upfront administration of GP IIb/IIIa inhibitors (GPIs) has shown to reduce early stent thrombosis (ST) compared to standard of care in BMS and DES. Since the use of GPIs was limited in BVS studies, the effect of GPIs on the rate of BVS-associated ScT is largely unknown. This is the first study investigating whether a planned use of GPIs during implantation of the Absorb BVS represents a safe and effective strategy in reducing ScT. In a retrospective chart review of 22 patients undergoing PCI with BVS implantation and planned GPI administration, no acute ScT, in-hospital MACE, or in-hospital major/minor bleeding events were observed. Bleeding reduction strategies such as shorter GPI infusion and radial access were implemented. This study provides valuable preliminary evidence on the benefit and safety in using planned GPI administration to reduce the incidence of ScT after implantation of BVS.

    Author bio

    Cardiovascular Revascularization Medicine, 2018-12-01, Volume 19, Issue 8, Pages 956-959, Copyright © 2018 Elsevier Inc.



    Click here to read the original post on Science Direct

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details